Market Overview

Oppenheimer Reports On Auxilium Partnership With Asahi Kasei Pharma


In a report published by Oppenheimer, Auxilium Pharmaceuticals (NASDAQ: AUXL) announced an outlicensing partnership with Asahi Kasei Pharma to develop and commercialize XIAFLEX in Japan for Dupuytren's contracture and Peyronie's disease.

Oppenheimer said that AUXL will receive a $15M up-front payment, $37M in potential payment developmental and regulatory milestones, and $210M in sales based milestones. “We expect Asahi to begin clinical trials in Dupuytren's contracture during 2012, with timing for trials in Peyronie's disease unknown at this point. Importantly, Asahi currently has ~700 sales representatives and is active in similar therapeutic verticals. We are updating our model to reflect this outlicensing arrangement, but our EPS estimates through 2012 are unchanged.”

Auxilium Pharmaceuticals closed yesterday at $22.05.

Posted-In: Auxilium Pharmaceuticals OppenheimerAnalyst Color Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Lihua International Initiates Share Repurchase Under $15M Buyback Program

Interxion Reports Q4 EPS of €0.20